Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy

Seleeke Flingai,Emily M. Plummer,Ami Patel,Sujan Shresta,Janess M. Mendoza,Kate E. Broderick,Niranjan Y. Sardesai,Kar Muthumani& David B. Weiner

Abstract
Dengue virus (DENV) is the most important mosquito-borne viral infection in humans. In recent years, the number of cases and outbreaks has dramatically increased worldwide. While vaccines are being developed, none are currently available that provide balanced protection against all DENV serotypes. Advances in human antibody isolation have uncovered DENV neutralizing antibodies (nAbs) that are capable of preventing infection from multiple serotypes. Yet delivering monoclonal antibodies using conventional methods is impractical due to high costs. Engineering novel methods of delivering monoclonal antibodies could tip the scale in the fight against DENV. Here we demonstrate that simple intramuscular delivery by electroporation of synthetic DNA plasmids engineered to express modified human nAbs against multiple DENV serotypes confers protection against DENV disease and prevents antibody-dependent enhancement (ADE) of disease in mice. This synthetic nucleic acid antibody prophylaxis/immunotherapy approach may have important applications in the fight against infectious disease.

http://www.nature.com/articles/srep12616#additional-information